<DOC>
	<DOCNO>NCT00223938</DOCNO>
	<brief_summary>This phase 4 clinical investigation efficacy safety Ferrlecit maintenance iron store serum hemoglobin concentration hemodialysis patient receive Erythropoietin .</brief_summary>
	<brief_title>Study Efficacy Safety Ferrlecit Maintenance Dosing Hemodialysis Patients .</brief_title>
	<detailed_description>A Multi-Center , Open-Label , Parallel Group Study efficacy safety Ferrlecit Maintenance Iron Stores Serum Hemoglobin Concentration Hemodialysis Patients Receiving Erythropoietin . Patients normal iron index receive one two dos Ferrlecit administer weekly throughout treatment period . Efficacy ass designate timepoints throughout study last Ferrlecit dose .</detailed_description>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male female , 18 year old old . Have receive chronic hemodialysis therapy On stable EPO dose regimen . Have sign patient inform consent . Predetermined serum ferritin TSAT level . Clinical instability inability achieve adequate dialysis , abnormal serum albumin serum glucose . Pregnant lactating . A known sensitivity Ferrlecit Scheduled renal transplant . A serious concomitant medical disorder incompatible participation study . Unable cooperate comply protocol . Use investigation agent within 30 day prior study course study . Judged investigator unsuitable enrollment reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>